Article summary
- Comparing Traditional Sinus Surgery and Modern In-Office Procedures
- Functional Endoscopic Sinus Surgery (FESS): The Traditional Approach
- Minimally Invasive Relief with NuVent Balloon Sinus Dilation
- Optimizing Recovery Outcomes with Propel Drug-Eluting Implants
- Managing Recurrent Polyps Non-Surgically with Sinuva
- Choosing the Right Setting: In-Office Comfort vs. Operating Room Safety
Comparing Traditional Sinus Surgery and Modern In-Office Procedures
When choosing a sinus treatment, patients often decide between traditional surgical methods and modern, minimally invasive procedures. The primary difference lies in the level of invasiveness, the setting of the procedure, and the recovery timeline. Traditional surgery typically involves removing bone or tissue to open sinus passages, whereas modern options like those offered by Medtronic focus on reshaping the anatomy with minimal disruption. Understanding these differences is essential for patients in the procedure decision stage to ensure the selected path aligns with their clinical needs and lifestyle goals.2,4
Functional Endoscopic Sinus Surgery (FESS): The Traditional Approach
Functional Endoscopic Sinus Surgery, or FESS, is the gold standard for treating severe chronic sinusitis or structural issues like a deviated septum. During FESS, a surgeon uses an endoscope to visualize the sinuses and removes diseased tissue, bone, or polyps that block drainage. This procedure is usually performed in an operating room under general anesthesia. While highly effective for complex cases, FESS is more invasive than office-based options and typically requires a longer recovery period, often ranging from one to two weeks, as the body heals from tissue removal.2,3
Minimally Invasive Relief with NuVent Balloon Sinus Dilation
For many patients with moderate chronic sinusitis, Medtronic’s NuVent™ EM Sinus Dilation System offers a less invasive alternative. Unlike traditional surgery that cuts tissue, NuVent uses a small, flexible balloon to gently expand and reshape the sinus openings. A unique feature of NuVent is its integration with image guidance technology, which acts like a GPS for the surgeon, providing a real-time map of the patient's unique anatomy. This allows for precise placement in an office setting under local anesthesia, often allowing patients to return to normal activities within 24 to 48 hours.5,6
Optimizing Recovery Outcomes with Propel Drug-Eluting Implants
Regardless of whether a patient undergoes traditional FESS or balloon dilation, the healing process is critical. Medtronic's Propel™ family of drug-eluting sinus implants is designed to maintain the surgical opening and improve long-term results. Once placed, the Propel implant acts as a spring-like support to keep the sinus open while gradually releasing mometasone furoate, an anti-inflammatory steroid, directly into the sinus lining. This targeted delivery is clinically proven to reduce the risk of scarring and the need for follow-up interventions or oral steroids, eventually dissolving on its own within 30 to 45 days.7,9
Managing Recurrent Polyps Non-Surgically with Sinuva
Patients who have previously had sinus surgery but struggle with recurrent nasal polyps may feel discouraged by the prospect of another operation. Medtronic's Sinuva™ Sinus Implant provides a non-surgical bridge. Placed during a routine office visit, Sinuva is a specialized stent that opens the sinus cavity and delivers anti-inflammatory medication directly to the polyps for up to 90 days. This targeted approach is proven to shrink polyps and significantly reduce the need for revision surgery, offering a bridge for patients who want to avoid the operating room while regaining their sense of smell and breathing clarity.10,11
Choosing the Right Setting: In-Office Comfort vs. Operating Room Safety
The decision between an in-office procedure and an operating room surgery depends on several factors, including the severity of the sinus disease and patient preference. In-office procedures using local anesthesia avoid the risks and 'brain fog' associated with general anesthesia, while also reducing facility costs and time away from work. However, traditional surgery in an operating room may be safer and more effective for patients with significant anatomical obstructions or extensive disease. Consulting with an ENT specialist who utilizes Medtronic's full suite of technologies ensures a personalized recommendation based on a comprehensive CT scan and clinical history.1,2
Frequently Asked Questions
The Medtronic Propel drug-eluting stent is a breakthrough in post-operative care, offering dual benefits: mechanical support and localized medication delivery. By physically holding the sinus passage open, it prevents the middle turbinate from scarring to the side of the nose. Simultaneously, it releases mometasone furoate, a corticosteroid that reduces inflammation and prevents the regrowth of polyps. Clinical studies have shown that Propel reduces the risk of scarring by 70% and decreases the need for oral steroids by 35%, leading to more predictable and successful long-term outcomes compared to surgery alone without a drug-eluting implant.8,9
Sinuva is a non-surgical treatment option specifically indicated for adults who have already undergone ethmoid sinus surgery but are experiencing a recurrence of nasal polyps. Unlike traditional revision surgery, which involves another trip to the operating room for tissue removal, Sinuva is a stent placed in the office under local anesthesia. It provides continuous, targeted steroid delivery for 90 days to shrink the polyps and reduce inflammation. In clinical trials, approximately 6 out of 10 patients treated with Sinuva no longer required a repeat surgery, making it a powerful tool for managing chronic polyp disease conservatively.10,11
Recovery times vary significantly between settings. Patients who undergo in-office procedures like balloon dilation usually experience minimal discomfort and can often return to work or their normal routine within 24 to 48 hours. In contrast, traditional functional endoscopic sinus surgery (FESS) performed in an operating room involves more extensive healing of the nasal mucosa and bone. Most FESS patients require one to two weeks of downtime and may experience temporary fatigue, congestion, and mild bleeding. Utilizing Medtronic technologies like PROPEL™ mometasone furoate sinus implants can help the healing process.3,4
For many patients, in-office procedures are considered safer because they eliminate the risks associated with general anesthesia, such as respiratory issues or adverse reactions to sedative drugs. In an office setting, local anesthesia is used, meaning the patient remains awake and comfortable, which also reduces the overall physiological stress on the body. However, 'safety' is relative to the complexity of the disease. For very severe cases, the controlled environment of an operating room is necessary to manage potential complications. Your ENT doctor will weigh these factors to determine the safest and most effective environment for your specific condition.2,3
Important Safety Information
PROPEL™ mometasone furoate sinus implants
The PROPEL Family of sinus implants are indicated to deliver a steroid drug locally and maintain the sinus opening after sinus surgery in patients 18 years of age or older:
PROPEL in the ethmoid sinus, PROPEL Mini in the ethmoid sinus and frontal sinus opening, and PROPEL Contour in the frontal and maxillary sinus openings. Patients allergic to the drug (mometasone furoate) or ingredients of the implant should not receive PROPEL.
It is not known if the implant is safe and effective in women that are pregnant or nursing.
Common side effects include infection, headache, and nose bleeds.
Risks related to the implant include pain/pressure, movement of the implant (within or out of the sinus) and potential side effects of steroids. For more information on the risks and benefits of PROPEL sinus implants, talk to your doctor or review the FDA approved labeling at www.manuals.medtronic.com. Rx only.
SINUVA™ (mometasone furoate) Sinus Implant
Indication & Important Safety Information
INDICATION
SINUVA™ (mometasone furoate) Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Patients with known hypersensitivity to mometasone furoate or any of the ingredients of the SINUVA™ Sinus Implant.
WARNINGS AND PRECAUTIONS
Local Nasal Adverse Reactions
Monitor nasal mucosa adjacent to the SINUVA™ Sinus Implant for signs of:
Healthcare Professional Facing Materials
- Bleeding (epistaxis)
- Irritation
- Infection
- Perforation
Avoid use in patients with nasal ulcers or trauma.
Glaucoma and Cataracts
Nasal steroids may result in the development of glaucoma and/or cataracts. These were not observed in patients from one randomized controlled clinical study (N = 53) with bilateral SINUVA™ Sinus Implants, but close monitoring is warranted in patients with:
- Changes in vision
- History of increased intraocular pressure
- Glaucoma
- Cataracts
Hypersensitivity Reactions Hypersensitivity reactions including rash, pruritus, and angioedema have been reported with corticosteroid use.
Immunosuppression and Risk of Infections
Patients using corticosteroids, including SINUVA™ Sinus Implant, may be more susceptible to infections.
Safety and effectiveness have not been established in pediatric patients under 18 years, and SINUVA™ is not indicated for this population.
Corticosteroids should be used with caution in patients with:
- Active or latent tuberculosis infection of the respiratory tract
- Untreated fungal, bacterial, viral, or parasitic infections
- Ocular herpes simplex
Hypercorticism and Adrenal Suppression If corticosteroid effects such as hypercorticism or adrenal suppression occur, consider sinus implant removal.
ADVERSE REACTIONS
The most common adverse reactions observed (>1% of subjects) in clinical studies were:
- Asthma
- Headache
- Epistaxis
- Presyncope
- Bronchitis
- Otitis media
- Nasopharyngitis
POSTMARKETING EXPERIENCE
The following adverse reactions have been identified during post-approval use of the SINUVA™ Sinus Implant:
- Implant migration
- Lack of efficacy
- Nasal pain
- Headache
- Epistaxis
Rx only.
Please see Full Prescribing Information for SINUVA™ available at SINUVA.com/hcp.
NuVent
Sinus surgery (FESS & BSS) has associated risks, including:
- Tissue trauma
- Bleeding
- Infection
- Possible ophthalmic injury
Patients should always discuss their individual needs and the potential risks and benefits of any treatment or procedure with their doctor.
Balloon sinus dilation may cause minor side effects such as:
- Congestion
- Facial numbness
- Headache
- Tenderness
- Sinus pain or pressure.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.
